Abstract
BackgroundPatients with systemic lupus erythematosus (SLE) have a higher prevalence of osteoporosis and low bone mineral density (BMD) compared with the general population. Rituximab, a CD20 depleting antibody, has been...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
